ACM
APLS

AlphaCrest Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

AlphaCrest Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,556
Closed -$405K – 1231
2021
Q4 		$405K Buy
+8,556
New +$337K 0.02% 1169
2021
Q2 		– Sell
-18,500
Closed -$794K – 1215
2021
Q1 		$794K Buy
18,500
+10,400
+128% +$492K 0.04% 595
2020
Q4 		$463K Buy
+8,100
New +$343K 0.04% 692

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's APLS Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2022, closing a stake of 8,556 shares — an estimated $405K sold.

AlphaCrest Capital Management first reported a position in APLS in Q4 2020 and held it in 3 quarters. The position peaked at $794K in Q1 2021. 212 funds tracked by Wall St. Rank hold APLS as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 8,556 Apellis Pharmaceuticals shares in Q1 2022, an estimated $405K.
  • AlphaCrest Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • AlphaCrest Capital Management's Apellis Pharmaceuticals position peaked at $794K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.